Trials / Recruiting
RecruitingNCT07446400
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1, 4-arm, Open-label, Drug-drug Interaction Trial to Evaluate the Pharmacokinetics of Repinatrabit Oral Tablets When Co-administered With Ethinyl Estradiol/Norethindrone, Metformin, Carbamazepine, Rosuvastatin, and Methotrexate in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Repinatrabit | Oral tablet. |
| DRUG | EE/NE | Oral tablet. |
| DRUG | Metformin | Oral tablet. |
| DRUG | Rosuvastatin | Oral tablet. |
| DRUG | Methotrexate | Oral tablet. |
| DRUG | Carbamazepine | Oral tablet. |
Timeline
- Start date
- 2026-03-31
- Primary completion
- 2026-06-12
- Completion
- 2026-06-12
- First posted
- 2026-03-03
- Last updated
- 2026-04-13
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07446400. Inclusion in this directory is not an endorsement.